September 26, 2016 11:19 PM ET

Diversified Consumer Services

Company Overview of The University of Texas M. D. Anderson Cancer Center

Company Overview

The University of Texas M. D. Anderson Cancer Center is an educational institution that offers undergraduate and research programs to physicians, biomedical scientists, and other health-care professionals. The departments include behavioral medicine, biochemistry and molecular biology, cancer biology program, cancer genomics core laboratory, molecular and cellular oncology, molecular genetics, molecular hematology and therapy, molecular therapeutics, and molecular pathology. The University of Texas M. D. Anderson Cancer Center was founded in 1941 as Texas State Cancer Hospital and the Division of Cancer Research and changed its name to M. D. Anderson Hospital for Cancer Research of The Unive...

1515 Holcombe Boulevard

Houston, TX 77030

United States

Founded in 1989



Key Executives for The University of Texas M. D. Anderson Cancer Center

Age: 61
Executive Vice President and Physician-In-Chief
Chairman of Department of Health Disparities Research
Vice President and Head of the Division of Pharmacy
Compensation as of Fiscal Year 2016.

The University of Texas M. D. Anderson Cancer Center Key Developments

Golden Meditech Holdings Limited and MD Anderson Cancer Center Team Up to Create Cellenkos, Inc

Golden Meditech Holdings Limited and The University of Texas announced the creation of Cellenkos Inc. a start-up enterprise focused on umbilical cord blood derived T-regulatory cellular therapies. Cellenkos, to be based in Houston, is funded with an initial investment of USD 10 million with warrants to purchase an additional USD 10 million worth of shares by Golden Meditech and an independent strategic investor. The agreement covers technologies arising from the laboratory investigations of Simrit Parmar, M.D., associate professor in the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson. Cellenkos will build on Dr. Parmar's existing and potential future pre-clinical and clinical research to develop various T-reg-based therapies for clinical use in treating autoimmune diseases where the patient's T-reg cells are often defective and/or lower in number. These chronic and morbid diseases require long-term treatment with drugs that suppress the immune system that often have adverse side effects. Adoptive therapy with cord blood derived T-reg cells has the potential to replenish the immune system and impact patient care by providing novel, non-pharmacologic options.

Scripps Health and The University of Texas MD Anderson Cancer Center Announce Partnership Agreement to Create Scripps MD Anderson Cancer Center

Scripps Health and The University of Texas MD Anderson Cancer Center have reached a partnership agreement to create Scripps MD Anderson Cancer Center, a comprehensive and clinically integrated cancer care program in San Diego. Through this partnership, Scripps MD Anderson is part of MD Anderson Cancer Network, a global collaborative network of hospitals and health care systems dedicated to MD Anderson's mission to end cancer globally. The collaboration allows Scripps to combine its expertise with MD Anderson's knowledge and capabilities for Southern California, covering eight counties from Santa Barbara to the US-Mexico border. It will offer patients access to MD Anderson's world-renowned treatment protocols, standards of care, extensive clinical trials and translational research. Patients also will have access to comprehensive cancer care, including medical oncology, radiation oncology, surgical oncology, pathology, laboratory and diagnostic imaging, as well as other clinical and support services. Close collaboration between the two organizations will be a hallmark of the new Scripps MD Anderson. MD Anderson Cancer Center will bring a multidisciplinary approach to local cancer patients and provide a new dimension of innovative care and treatment options. Through joint tumor boards, MD Anderson also will provide opinions for diagnosis and treatment. The program will offer a patient-centered approach to care, with multidisciplinary teams of oncology specialists supporting patients and families in making informed, evidence-based medical decisions. It will also offer an array of patient support services, including genetic counseling, nurse navigation, integrative medicine, palliative care, imaging services and social worker assistance in one convenient, patient-friendly environment.

BioLineRx Has Signs Collaboration Agreement with the University of Texas MD Anderson Cancer Center

BioLineRx has signed a collaboration agreement with The University of Texas MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer. The study will be part of a strategic clinical research collaboration between Merck (in the U.S. and Canada) and MD Anderson Cancer Center aimed at evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with various treatments and novel drugs.

Similar Private Companies By Industry

Company Name Region
1-800-Dryclean, LLC United States
1-800-PHONESEX United States
125 Max Drycleaning Center LLC United States
180 Skills LLC United States
19Pencils, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact The University of Texas M. D. Anderson Cancer Center, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at